PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30647852-0	2018	Chronic lymphocytic leukemia cells from ibrutinib treated patients are sensitive to Axl receptor tyrosine kinase inhibitor therapy.	ibrutinib	40-49	AXL receptor tyrosine kinase	Homo sapiens	84-87	
30647852-3	2018	Ibrutinib-exposed CLL B-cells were treated with increasing doses (0.01- 0.50muM) of a new formulation of high-affinity Axl inhibitor, TP-0903 (tartrate salt), for 24 hours and LD50 doses were determined.	ibrutinib	0-9	AXL receptor tyrosine kinase	Homo sapiens	119-122	
30647852-5	2018	We detected sustained overexpression of Axl in CLL B-cells from CLL patients on ibrutinib treatment, suggests targeting Axl could be a promising strategy to overcome drug resistance and killing of CLL B-cells in these patients.	ibrutinib	80-89	AXL receptor tyrosine kinase	Homo sapiens	40-43	
30647852-5	2018	We detected sustained overexpression of Axl in CLL B-cells from CLL patients on ibrutinib treatment, suggests targeting Axl could be a promising strategy to overcome drug resistance and killing of CLL B-cells in these patients.	ibrutinib	80-89	AXL receptor tyrosine kinase	Homo sapiens	120-123